Help my MathBroad stroke observations on the J P Morgan BioTech conference....well over 250 companies making a presence, most are at pre-clinical stage development, many at phase two. I'm not a mathematical wiz but if companies (example) are trading at $13.00 (year high/low 4/18).......with average trading at 175k......and have yet to hit a home run with an established immunotherapy.........why would we not expect that Telesta should be at $1+ today with potential to $5+++?